{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:16:26Z","timestamp":1761714986313,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","primary-care-diabetes.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care Diabetes"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.pcd.2016.05.008","type":"journal-article","created":{"date-parts":[[2016,7,4]],"date-time":"2016-07-04T17:31:45Z","timestamp":1467653505000},"page":"425-433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Patient engagement impacts glycemic management with vildagliptin and vildagliptin\/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study)"],"prefix":"10.1016","volume":"10","author":[{"given":"Michel","family":"Hermans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Van Gaal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"R\u00e9zette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evis","family":"Daci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kris","family":"Denhaerynck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefaan","family":"Vancayzeele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lut","family":"De Meester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Yee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcd.2016.05.008_bib0100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nm0106-75","article-title":"Diabetes and obesity: the twin epidemics","volume":"12","author":"Smyth","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.pcd.2016.05.008_bib0105","unstructured":"If you\u2019re one of the world's 382 million diabetics, your wages may dip. Available at http:\/\/www.npr.org\/blogs\/goatsandsoda\/2015\/03\/16\/393332849\/if-youre-one-of-the-worlds-382-million-diabetics-your-wages-may-dip?utm_medium=RSS&utm_campaign=news (last accessed 09.07.15)."},{"key":"10.1016\/j.pcd.2016.05.008_bib0110","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1021\/jm030091l","article-title":"1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties","volume":"46","author":"Villhauer","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pcd.2016.05.008_bib0115","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1210\/jc.2006-1882","article-title":"The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients","volume":"92","author":"Balas","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.pcd.2016.05.008_bib0120","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.2337\/diacare.28.8.1936","article-title":"Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year","volume":"28","author":"Ahren","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2016.05.008_bib0125","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.diabres.2006.12.009","article-title":"Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes","volume":"76","author":"Pi-Sunyer","year":"2007","journal-title":"Diabet. Res. Clin. Pract."},{"key":"10.1016\/j.pcd.2016.05.008_bib0130","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2337\/dc06-1732","article-title":"Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin","volume":"30","author":"Bosi","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2016.05.008_bib0135","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1463-1326.2007.00820.x","article-title":"Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study","volume":"10","author":"Bolli","year":"2008","journal-title":"Diabet. Obes. Metab."},{"key":"10.1016\/j.pcd.2016.05.008_bib0140","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1463-1326.2006.00684.x","article-title":"Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study","volume":"9","author":"Garber","year":"2007","journal-title":"Diabet. Obes. Metab."},{"key":"10.1016\/j.pcd.2016.05.008_bib0145","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1464-5491.2007.02191.x","article-title":"Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes","volume":"24","author":"Schweizer","year":"2007","journal-title":"Diabet. Med."},{"key":"10.1016\/j.pcd.2016.05.008_bib0150","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1463-1326.2008.00994.x","article-title":"Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy","volume":"11","author":"Ferrannini","year":"2009","journal-title":"Diabet. Obes. Metab."},{"key":"10.1016\/j.pcd.2016.05.008_bib0155","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.2165\/0003495-200868160-00009","article-title":"Vildagliptin: a review of its use in the management of type 2 diabetes mellitus","volume":"68","author":"Croxtall","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.pcd.2016.05.008_bib0160","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1517\/14656566.2015.978289","article-title":"A review of gliptins for 2014","volume":"16","author":"Scheen","year":"2015","journal-title":"Exp. Opin. Pharmacother."},{"key":"10.1016\/j.pcd.2016.05.008_bib0165","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach\u2014update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucci","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2016.05.008_bib0170","unstructured":"Novartis, data on file."},{"key":"10.1016\/j.pcd.2016.05.008_bib0175","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1179\/2295333714Y.0000000018","article-title":"Effectiveness and tolerability of second-line therapy with vildagliptin versus other oral agents in type 2 diabetes (EDGE): post hoc subanalysis of the Belgian data","volume":"69","author":"Hoste","year":"2014","journal-title":"Acta Clin. Belg."},{"key":"10.1016\/j.pcd.2016.05.008_bib0180","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/00019053-200725040-00002","article-title":"Measuring patient reported outcomes in solid organ transplant recipients: an overview of instruments developed to date","volume":"25","author":"Cleemput","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.pcd.2016.05.008_bib0185","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-Year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.pcd.2016.05.008_bib0190","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/ijcp.12252","article-title":"Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE)","volume":"67","author":"Mathieu","year":"2013","journal-title":"Int. J. Clin. Pract."}],"container-title":["Primary Care Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991816300420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991816300420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:55:29Z","timestamp":1761695729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1751991816300420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S1751991816300420"],"URL":"https:\/\/doi.org\/10.1016\/j.pcd.2016.05.008","relation":{},"ISSN":["1751-9918"],"issn-type":[{"type":"print","value":"1751-9918"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient engagement impacts glycemic management with vildagliptin and vildagliptin\/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study)","name":"articletitle","label":"Article Title"},{"value":"Primary Care Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcd.2016.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}